Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Hjalmar C. van Santvoort

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0007-1218-2883; OpenAlex author ID A5009834418. Sources: ClinicalTrials.gov.

Their work

Papers
124 (first author 2, last author 13)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
238
Papers, trials and grants by year

2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 4 papers · 2018: 6 papers, 1 trial · 2019: 4 papers · 2020: 5 papers · 2021: 12 papers · 2022: 16 papers · 2023: 11 papers · 2024: 19 papers · 2025: 16 papers · 2026: 24 papers

Papers 50 of 124

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Population. Last author DOI 10.1002/jso.70391↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Last author DOI 10.1016/j.ejca.2026.116956↗
  5. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  6. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  7. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  8. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  9. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  10. Pancreatic ductal adenocarcinoma: Clinical trials to watch. Last author DOI 10.1016/j.medj.2026.101268↗
  11. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  12. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  13. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  14. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  15. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  16. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  17. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  18. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  19. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  20. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  21. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  22. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  23. ASO Author Reflections: The Impact of Perioperative Treatment on Recurrence Treatment for Pancreatic Cancer. First author DOI 10.1245/s10434-025-18798-1↗
  24. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  25. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  26. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  27. Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01357-y↗
  28. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  29. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  30. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  31. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  32. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  33. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  34. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  35. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  36. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  37. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  38. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  39. The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells14090632↗
  40. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  41. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  42. 31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data. Co-author DOI 10.1002/jmri.29326↗
  43. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  44. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  45. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  46. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  47. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/sla.0000000000005977↗
  48. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  49. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  50. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗

Trials 1

  1. POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection Principal investigator NCT03400280↗

Closest collaborators

The 25 strongest of 238 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 93 shared papers, 2014–2026 · strength 13.67
  2. Marc G. Besselink · 90 shared papers, 2014–2026 · strength 12.41
  3. Lois A. Daamen · 57 shared papers, 2017–2026 · strength 9.68
  4. Bas Groot Koerkamp · 63 shared papers, 2017–2026 · strength 9.09
  5. Ignace H. J. T. de Hingh · 60 shared papers, 2014–2026 · strength 8.17
  6. Johanna W. Wilmink · 45 shared papers, 2016–2026 · strength 6.52
  7. Martijn W.J. Stommel · 44 shared papers, 2019–2026 · strength 6.38
  8. Vincent Erwin de Meijer · 40 shared papers, 2020–2026 · strength 5.89
  9. Casper H.J. van Eijck · 44 shared papers, 2014–2026 · strength 5.86
  10. Bert A. Bonsing · 39 shared papers, 2014–2026 · strength 5.21
  11. Sebastiaan Festen · 30 shared papers, 2021–2026 · strength 4.41
  12. Geert Kazemier M · 29 shared papers, 2016–2026 · strength 4.10
  13. Judith de Vos‐Geelen · 27 shared papers, 2018–2026 · strength 4.03
  14. Vincent P. Groot · 24 shared papers, 2017–2026 · strength 3.85
  15. Paul C. M. Andel · 17 shared papers, 2024–2026 · strength 3.34
  16. Marjolein Y.V. Homs · 20 shared papers, 2020–2026 · strength 3.33
  17. Iris W.J.M. van Goor · 20 shared papers, 2021–2026 · strength 3.29
  18. Thijs J. Schouten · 19 shared papers, 2021–2026 · strength 3.16
  19. Geertjan van Tienhoven · 23 shared papers, 2017–2026 · strength 3.12
  20. Robert C. Verdonk · 18 shared papers, 2022–2026 · strength 3.10
  21. Gijs A. Patijn · 23 shared papers, 2016–2026 · strength 3.09
  22. Hanneke W.M. van Laarhoven · 22 shared papers, 2018–2026 · strength 3.06
  23. Christopher Lee Wolfgang · 15 shared papers, 2017–2026 · strength 2.62
  24. Vincent B. Nieuwenhuijs · 18 shared papers, 2020–2026 · strength 2.48
  25. Thomas F. Stoop · 13 shared papers, 2024–2026 · strength 2.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.